Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.
NASA’s Artemis II moon mission highlights the Space Coast’s 2026 launch manifest, which also could see Blue Origin’s moon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback